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Purpose: To evaluate the efﬁ  cacy, safety and tolerability of changing to travoprost BAK-free 
from prior prostaglandin therapy in patients with primary open-angle glaucoma or ocular 
hypertension.
Design: Prospective, multi-center, historical control study.
Methods: Patients treated with latanoprost or bimatoprost who needed alternative therapy 
due to tolerability issues were enrolled. Patients were surveyed using the Ocular Surface Disease 
Index (OSDI) to evaluate OSD symptoms prior to changing to travoprost BAK-free dosed once 
every evening. Patients were re-evaluated 3 months later.
Results: In 691 patients, travoprost BAK-free demonstrated improved mean OSDI scores 
compared to either latanoprost or bimatoprost (p  0.0001). Patients having any baseline 
OSD symptoms (n = 235) demonstrated signiﬁ  cant improvement after switching to travoprost 
BAK-free (p  0.0001). In 70.2% of these patients, symptoms were reduced in severity by at 
least 1 level. After changing medications to travoprost BAK-free, mean intraocular pressure 
(IOP) was signiﬁ  cantly decreased (p  0.0001). Overall, 72.4% preferred travoprost BAK-free 
(p < 0.0001, travoprost BAK-free vs prior therapy). Travoprost BAK-free demonstrated less 
conjunctival hyperemia than either prior therapy (p  0.0001).
Conclusions: Patients previously treated with a BAK-preserved prostaglandin analog who are 
changed to travoprost BAK-free have clinically and statistically signiﬁ  cant improvement in their 
OSD symptoms, decreased hyperemia, and equal or better IOP control.
Keywords: glaucoma, prostaglandin analog, travoprost, latanoprost, bimatoprost, preservative, 
benzalkonium chloride, ocular surface disease
Introduction
Symptoms of dry eye are reported in approximately 15% of the elderly according 
to a population-based study conducted by Schein et al (1997). However, it has 
recently been reported by Fechtner et al (2008) that prevalence of ocular surface 
disease (OSD) symptoms in glaucoma patients is 48.4% and the severity of OSD 
symptoms increases with the number of medications used. This increased occur-
rence of dry eye symptoms in glaucoma patients is of particular interest. Glaucoma 
patients may be at an increased risk of developing dry eye symptoms due to the 
long-term use of intraocular pressure (IOP)-lowering medications. Many of these 
medications contain preservatives which have been associated with an increase 
in the prevalence of ocular signs and symptoms (Kuppens et al 1995; Pisella et al 
2002; Jaenen et al 2007). Benzalkonium chloride (BAK), the most commonly used 
preservative in ophthalmic preparations, has a high afﬁ  nity for membrane proteins 
and may accumulate in ocular tissues, inducing cell toxicity and/or cell death in a 
dose-dependent manner (Yee 2007).Clinical Ophthalmology 2008:2(3) 614
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Introduced in 1996, the prostaglandin analog class of 
IOP-lowering medications has become the most common 
ﬁ  rst-line therapy for the treatment of elevated IOP in the US 
generally because of its efﬁ  cacy and systemic tolerability. 
However, prostaglandin analog preparations have tradition-
ally been preserved with BAK and have been shown to 
damage ocular tissue by inducing apoptosis and increasing 
the concentrations of inﬂ  ammatory markers (Noecker et al 
2004; Baudouin et al 2007).
Travoprost BAK-free ophthalmic solution (TRAV-
ATAN Z®, Alcon Laboratories, Inc., Fort Worth, TX, 
USA) was recently introduced as the first commercially 
available preparation of a prostaglandin analog preserved 
without BAK. Travoprost BAK-free contains an ionic 
buffered preservative system, sofZia™. Recently, Lewis 
et al compared travoprost BAK-free with BAK-preserved 
travoprost (TRAVATAN®, Alcon Laboratories, Inc., Fort 
Worth, TX, USA) in a randomized, multi-center, paral-
lel, double-masked trial (Lewis et al 2007). IOP control 
was statistically equivalent between treatment groups 
and less conjunctival hyperemia was observed with the 
BAK-free preparation, although it was not statistically 
significant.
The toxicity of travoprost with and without BAK has been 
compared with the commercial preparation of latanoprost 
in several laboratory trials. Several investigators have used 
corneal and conjunctival cell cultures to demonstrate that 
travoprost BAK-free is associated with less apoptosis and 
cytotoxicity compared with latanoprost (preserved with 
0.02% BAK) (Yee et al 2006; Baudouin et al 2007; Epstein 
et al 2008). Similarly, McCarey and Edelhauser (2007) 
reported that treatment with travoprost BAK-free had no 
negative effect on the integrity of corneal epithelial tight 
junctions, whereas latanoprost use was associated with 
signiﬁ  cant loss of tight junctions (p  0.0001). In addition, 
Whitson et al (2006) found little corneal toxicity in rabbits 
treated with travoprost BAK-free, whereas latanoprost caused 
superﬁ  cial cell loss. Unfortunately, few data are available 
that evaluate the clinical beneﬁ  t of eliminating BAK from 
prostaglandin analog therapy.
The purpose of the present study was to exam-
ine the safety, tolerability and efficacy of travoprost 
BAK-free ophthalmic solution compared to previous 
use of either latanoprost or bimatoprost monotherapy. 
The Ocular Surface Disease Index (OSDI), a validated 
English-language questionnaire, was used examine the 
prevalence of dry eye/OSD complaints in glaucoma 
patients (Schiffman et al 2000).
Methods
Patients
Eligible patients were adults with open-angle glaucoma 
or ocular hypertension treated with either latanoprost 
(Xalatan®, Pﬁ  zer Inc., New York, NY, USA) or bimatoprost 
(Lumigan®, Allergan, Irvine, CA, USA) monotherapy 
who demonstrated a need for greater tolerability and 
were judged by their physician to be a good candidate for 
travoprost BAK-free ophthalmic solution. The design was 
a multi-center, prospective, open-label, historical control 
study. Patients enrolled for this study were recruited from 
65 clinical sites across the US.
Patients included in this study were at least 18 years 
of age; able to read and complete the OSDI questionnaire 
in English; had a clinical diagnosis of ocular hypertension 
or primary open-angle, pigment dispersion, or exfoliation 
glaucoma; treated with either latanoprost or bimatoprost 
monotherapy for at least 1 week, the last dose of which 
was instilled correctly so the patient was within the dos-
ing cycle at Visit 1; best-corrected Snellen visual acuity 
of 20/200 or better in each eye; and IOP 30 mmHg in 
both eyes.
Exclusion criteria included primary or secondary glau-
coma not listed in inclusion criterion; untreated history of 
narrow angles in either eye; concurrent infectious/non-
infectious conjunctivitis, keratitis, or uveitis in either eye; 
blepharitis (non-clinically signiﬁ  cant or prostaglandin-
induced conjunctival injection was allowed); intraocular 
conventional surgery or laser surgery in study eye(s) less 
than 3 months prior to Visit 1; risk of visual ﬁ  eld or visual 
acuity worsening as a consequence of participation in the 
trial; anticipated use of ocular or oral corticosteroids for 
more than 2 weeks total during the trial; and contact lens 
use in the study eye(s).
Procedures
All patients signed an Institutional Review Board-approved 
informed consent agreement and met the inclusion/exclu-
sion criteria before any procedures were performed. Eligible 
patients had an ocular and systemic history taken. Patients 
then discontinued previous therapy and received 1 bottle of 
travoprost BAK-free ophthalmic solution (TRAVATAN Z®, 
Alcon Laboratories, Inc., Fort Worth, TX, USA) and a pre-
scription for TRAVATAN Z®, to be used once every evening 
in the study eye(s).
Patients returned for Visit 2 at Week 12, which must 
have been conducted at the same time of day (± 1 hour) as 
Visit 1. Patients who did not take their travoprost BAK-free Clinical Ophthalmology 2008:2(3) 615
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as prescribed the day before the visit were rescheduled. 
Patients may have been examined by the investigator at any 
time between Visits 1 and 2 but these were not considered 
study visits. However, if the patient was discontinued from 
travoprost BAK-free before Visit 2, that visit was considered 
a study exit visit.
At Visits 1 and 2, Goldmann applanation tonometry, 
conjunctival hyperemia grading (by a photographic scale), 
Snellen visual acuity, and slit lamp biomicroscopy assess-
ments were made. Patients completed the OSDI symptom 
questionnaire at Visits 1 and 2 and provided a global prefer-
ence response at Visit 2. Additionally, adverse events were 
recorded at Visit 2.
Administration and calculation
of OSDI score
The OSDI is a validated questionnaire designed to measure 
the severity of symptoms associated with ocular surface 
disease (Schiffman et al 2000). The OSDI questionnaire 
was handed to the patients and they were instructed to 
answer the questions on their own without any assistance. 
Patients were asked to answer all questions by placing a 
check in the box that corresponded to their symptoms. The 
individual answers corresponded to a speciﬁ  c value; all of 
the time = 4, most of the time = 3, half of the time = 2, some 
of the time = 1, and none of the time = 0. Those questions 
to which the patients responded not applicable (N/A) and 
questions that were not answered were not factored into the 
score calculation.
Total OSDI Score =
 
(Sum of Score for All Questions Answered) × (25)
(Total # of Questions Answered)
The classification of normal, mild, moderate, or 
severe OSD was determined on a scale from 0 to 100.
OSD severity was classiﬁ  ed as follows: normal (0–12), 
mild (13–22), moderate (23–32), and severe (33–100).
Statistics
All data analyses were two-sided. An α-level of 0.05 was 
used to declare statistical significance. A per-protocol, 
average eye analysis was used. Internet-based electronic data 
capture was used for the trial.
The change in IOP from previous prostaglandin analog 
therapy (latanoprost or bimatoprost), to travoprost BAK-free 
was analyzed by the paired t-test within each prior treatment 
or the combined population (Book 1978).
A one-way ANOVA test also was utilized to evaluate 
differences in hyperemia grading (grade 0–3) and OSDI 
scores for both prior medications compared to travoprost 
BAK-free. The paired t-test within an ANOVA was used 
to evaluate differences among individual preparations. 
A modiﬁ  ed Bonferroni correction (α/6) was used to adjust 
p-level for individual OSDI questions in order to declare 
statistical signiﬁ  cance.
Adverse events related to travoprost BAK-free therapy 
were not analyzed statistically because unsolicited adverse 
event data related to bimatoprost or latanoprost therapy were 
not collected at Visit 1.
Results
Patients
Enrolled in this study were 813 patients, of whom 17 were 
protocol violations. Of the 796 eligible patients, 105 (13%) did 
not complete the study. Therefore, 691 completed the study 
per protocol. The most common reasons for early discontinu-
ation were related and unrelated adverse events (n = 45; 6%), 
lost to follow-up (n = 17; 2%), non-compliance (n = 11; 1%), 
and withdrew consent (n = 10; 1%). The most common 
adverse events leading to discontinuation were conjunctival 
hyperemia (n = 20; 3%), ocular irritation (n = 12; 2%), burn-
ing (n = 7; 1%), and 5 each (1%) for reduced vision and itch-
ing. No other ocular complaint was cited more than 2 times. 
Patients may have had more than 1 complaint.
Of 796 eligible patients, 61% were female and 77% were 
Caucasian (Table 1). The average age was 69.4 ± 11.8 years. 
Most patients (89%) had primary open-angle glaucoma. The 
most common associated ocular diagnoses at baseline were 
conjunctival hyperemia (n = 33; 4%), cataract (n = 20; 3%), 
and pseudophakia (n = 17; 2%); the most common systemic 
diagnoses were systemic hypertension (n = 576; 72%), lipid 
disorder (n = 254; 32%), and diabetes (n = 220; 28%).
Ocular surface disease symptoms
In a broad examination of OSDI scores, travoprost 
BAK-free demonstrated improved mean global scores 
(8.7 ± 11.3) compared with either latanoprost (12.0 
± 13.2, p  0.0001) or bimatoprost therapy (13.2 
± 14.6, p  0.0001; Figure 1). Use of travoprost 
BAK-free resulted in significantly improved scores 
versus prior therapy whether latanoprost and bimato-
prost were considered individually or were combined 
(p  0.0001). Individual questions which showed 
signiﬁ  cant improvement after travoprost BAK-free ther-
apy, following the Bonferroni correction, were sensitivity Clinical Ophthalmology 2008:2(3) 616
Henry et al
to light, gritty feeling, painful eyes, blurred vision, poor 
vision, reading difﬁ  culties, driving difﬁ  culties at night, 
working with the computer, windy conditions, and low 
humidity (p  0.0007).
In a subset examination of the data, patients were 
grouped according to severity of their baseline visit (Visit 1) 
OSDI score (normal, mild, moderate, or severe). Patients 
remained grouped according to baseline OSDI scores and 
were analyzed for changes at Visit 2. Those patients clas-
siﬁ  ed as normal (n = 456) had a baseline score of 4.7 ± 3.8 
compared to 4.9 ± 6.8 at Visit 2, which was not signiﬁ  cantly 
different (p = 0.49; Figure 2). The mean baseline score 
for patients with mild symptoms (n = 112) was 17.0 ± 3.0 
and improved to a mean score of 9.6 ± 7.7 after travoprost 
therapy; patients with moderate symptoms (n = 59) 
improved from 27.1 ± 2.1 to 19.2 ± 13.5; and patients with 
severe symptoms (n = 64) improved from 45.8 ± 10.9 to 
24.6 ± 17.9. When symptomatic patients (those with mild, 
moderate, or severe symptoms) were pooled, their scores 
were reduced from a mean of 27.4 ± 13.5 to a mean of 
16.1 ± 14.2. All changes from baseline in symptomatic 
patients were statistically signiﬁ  cant (p  0.0001). Regard-
less of OSD severity, the use of travoprost BAK-free for 
3 months reduced the mean OSDI score by 1 category of 
severity: severe to moderate, moderate to mild, and mild 
to normal.
The use of travoprost BAK-free for 3 months reduced 
the mean OSDI score by at least 1 category of severity 
(severe to moderate, moderate to mild, or mild to normal) 
in 70.2% of the 235 patients with OSD symptoms at 
baseline (Table 2). Fifty-seven (46.3%) of 123 moderate 
or severe patients improved by a reduction in severity by 
at least 2 levels. Of the 64 severe patients, 15 (23.4%) 
improved to normal, decreasing the level of severity by 
3 levels.
The number of patients with a clinically signiﬁ  cant 
reduction in OSDI scores, deﬁ  ned as 9 points or more, was 
also examined (Figure 3). Of the 235 patients with mild to 
severe symptoms, 134 (57.0%) had a reduction of 9 points 
or more from their baseline OSDI score after 3 months of 
treatment with travoprost BAK-free. Approximately half 
of the patients with mild (49.1%) or moderate (49.2%) 
symptoms achieved clinically signiﬁ  cant improvement, 
as did over three-quarters (78.1%) of patients with severe 
symptoms.
Table 1 Patient demographics
Eligible patients 
N = 796
n (%)
Age (mean years ± SD) 69.4 ± 11.8
Gender
   Male
   Female
311 (39)
485 (61)
Race
   Caucasian
   African-American
   Hispanic
   Asian
   Other
610 (77)
110 (14)
39 (5)
31 (4)
6 (1)
Diagnosis
   Primary open-angle glaucoma
   Ocular hypertension
   Exfoliative glaucoma
   Pigment dispersion glaucoma
708 (89)
77 (10)
8 (1)
3 (0.4)
15
12
9
6
3
0
N = 476 N = 215
8.7 8.7 8.7
12.4
13.2
12.0
N = 691
Latanoprost
Latanoprost/Bimatoprost
Travoprost BAK-free
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Figure 1 Improvement in ocular surface disease index scores with travoprost BAK-free according to previous prostaglandin analog use. *p  0.0001.Clinical Ophthalmology 2008:2(3) 617
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Intraocular pressure
After a change in medications from their previous prosta-
glandin analog to travoprost BAK-free, patients experienced 
a statistically signiﬁ  cant reduction in IOP (17.3 ± 3.6 vs. 
16.6 ± 3.8 mmHg; p  0.0001; Figure 4). When IOP was 
analyzed by speciﬁ  c prior prostaglandin analog therapy, a 
signiﬁ  cant decrease in IOP was observed after changing 
from latanoprost to travoprost (p  0.0001), but not from 
bimatoprost to travoprost (p = 0.5245).
Hyperemia
Physicians graded hyperemia for all patients on a 0 to 3 
scale at both visits. The baseline hyperemia scores were 
statistically different between latanoprost (0.7 ± 0.7) and 
bimatoprost (1.0 ± 0.9; p  0.0001; Figure 5). How-
ever, both groups experienced a significant decrease 
in hyperemia with travoprost BAK-free (0.5 ± 0.6 and 
0.6 ± 0.7, respectively; p  0.0001). An examination 
of hyperemia, irrespective of the patient’s previous 
prostaglandin analog use, also resulted in a statistically 
significant decrease in the hyperemia score, from 
0.8 ± 0.8 to 0.5 ± 0.6 (p  0.0001).
Visual acuity
LogMAR visual acuity was signiﬁ  cantly better with travo-
prost BAK-free versus prior therapy (0.167 ± 0.140 versus 
0.174 ± 0.151, p = 0.04).
Adverse events
The most commonly reported unsolicited adverse events 
with travoprost BAK-free were conjunctival hyperemia 
(n = 49; 6%) and change in visual acuity (n = 28; 4%; 
Table 3). There were 5 serious adverse events in 3 patients: 
non-speciﬁ  c infection, vomiting and shortness of breath, 
aortic dissection, metastatic cancer of the liver, and 
abdominal rash. Investigators reported that none of these 
events were related to travoprost BAK-free.
Figure 2 Improvement in ocular surface disease index scores with travoprost BAK-free according to baseline severity. *p  0.0001.
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Table 2 Patients with an OSDI score that improved by at least one level of severity
OSDI severity 
grouping (baseline)
Patients improved 
to normal [n (%)]
Patients improved 
to mild [n (%)]
Patients improved 
to moderate [n (%)]
Patients improved 
by at least 1 level [n (%)]
Mild (n = 112) 79 (70.5%) N/A N/A 79 (70.5%)
Moderate (n = 59) 21 (35.6%) 18 (30.5%) N/A 39 (66.1%)
Severe (n = 64) 15 (23.4%) 21 (32.8%) 11 (17.2%) 47 (73.4%)
Mild + Moderate + 
Severe (n = 235)
115 (48.9%) 39 (16.6%) 11 (4.7%) 165 (70.2%)
Abbreviations: OSDI, Ocular Surface Disease Index.Clinical Ophthalmology 2008:2(3) 618
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Patient preference
The results for the global patient preference survey 
found 500 of the 691 patients (72.4%) favored travo-
prost BAK-free while 191 (27.6%) preferred the prior 
prostaglandin analog (p  0.0001; Table 4). An exami-
nation based on speciﬁ  c prior prostaglandin analog use 
demonstrated that 74.6% of the patients previously using 
latanoprost and 67.4% previously using bimatoprost pre-
ferred travoprost BAK-free.
Discussion
The purpose of this study was to examine the safety, 
tolerability and efﬁ  cacy of travoprost BAK-free ophthalmic 
solution compared with previous use of either latanoprost or 
bimatoprost monotherapy in a typical clinical situation.
The OSDI was the primary tool used to assess symptoms 
related to ocular surface disease (Ozcura et al 2007). After 
the change to travoprost BAK-free, global mean OSDI 
scores were signiﬁ  cantly reduced from scores while taking 
latanoprost and bimatoprost, evaluated together or individu-
ally. This demonstrated statistically signiﬁ  cant improvement 
in mean global scores on travoprost BAK-free (8.7 ± 11.3) 
from either latanoprost (12.0 ± 13.2) or bimatoprost therapy 
(13.2 ± 14.6).
In a subset examination of the data, patients were 
grouped according to baseline visit OSDI score. 
Figure 3 Clinically signiﬁ  cant improvement (9 points) in ocular surface disease index scores with travoprost BAK-free according to baseline severity.
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Figure 4 Change in mean IOP with travoprost BAK-free according to previous prostaglandin analog use. *p  0.0001.Clinical Ophthalmology 2008:2(3) 619
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Regardless of the severity of OSD symptoms, the use of 
travoprost BAK-free for 3 months significantly reduced 
the mean OSDI score in each group enough to reduce 
the category of severity to the next lower level (severe 
to moderate, moderate to mild, and mild to normal). 
Additionally, the shifts in mean OSDI scores for each of 
the individual groups as well as for a group combining 
mild, moderate, and severe scores was approximately 9 
points or greater (range, 8.0–21.2), confirming the clinical 
significance of this improvement (Miller et al 2006). The 
data were also examined on a per patient basis to explore 
how individual patients responded. Over 70% of patients 
experienced a decrease in their OSD symptoms by at least 
1 level of severity after 3 months on travoprost BAK-free. 
Even more impressive is the fact that almost one quarter 
of the patients with a severe baseline score improved to 
the normal range after 3 months. Furthermore, 57% of 
symptomatic patients had a clinically significant improve-
ment in their OSD symptoms. The absence of BAK in 
the travoprost preparation may have contributed to the 
improved comfort experienced by the study patients. 
Consequently, by using travoprost BAK-free, a physi-
cian now has a way to prescribe chronic prostaglandin 
therapy while possibly helping improve a patient’s OSD 
symptoms.
These findings may have clinical importance for 
glaucoma patients beyond the lessening of OSD symp-
toms. A consequence of a more comfortable ocular 
surface, as a result of using travoprost BAK-free, may 
potentially be an improvement in patient adherence to 
the IOP-lowering regimen, which could in turn improve 
IOP control.
This study demonstrated that IOP was significantly 
reduced after the initiation of travoprost BAK-free therapy 
compared to prior prostaglandin analog therapy. The results 
of this study are consistent with the travoprost BAK-free 
regulatory trial, which demonstrated travoprost BAK-free 
was at least as efﬁ  cacious as the BAK-preserved preparation 
of travoprost (Lewis et al 2007). Furthermore, a randomized, 
double-masked study by Gross and colleagues demonstrated 
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Figure 5 Change in mean hyperemia scores with travoprost BAK-free according to previous prostaglandin analog use. *p  0.0001.
Table 3 Ophthalmic adverse events with travoprost BAK-free
Description n
Hyperemia 49
Change in visual acuity 28
Burning 14
Irritation 9
Adverse events with an incidence of at least 1%.
Table 4 Patient preference (per patient analysis)
Baseline 
prostaglandin 
analog
nP r e f e r r e d  
previous 
therapy
Preferred 
travoprost 
BAK-free
p-value
Latanoprost 476 25.4% 74.6% 0.0001
Bimatoprost 215 32.6% 67.4% 0.0001
Combined 691 27.6% 72.4% 0.0001Clinical Ophthalmology 2008:2(3) 620
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that the two formulations of travoprost (travoprost with BAK 
and travoprost BAK-free) had similar efﬁ  cacy, including a 
prolonged duration of action showing 6 mmHg reduction in 
IOP 60 hours after ﬁ  nal dose of either drug (Gross et al 2008). 
However, physicians must interpret the efﬁ  cacy data from the 
current trial with caution because of its open-label design, 
which may have introduced bias into the results for IOP.
Additionally, the reduction in conjunctival hyperemia 
experienced by patients after the initiation of travoprost 
BAK-free correlated well with reports that BAK has been 
shown to worsen conjunctival inﬂ  ammation (Noecker et al 
2004; Yee et al 2006; Kahook et al 2008). BAK might 
further worsen conjunctival hyperemia already present due 
to prostaglandin analog therapy, which is associated with 
nitric oxide synthesis within the conjunctival vessels (Astin 
et al 1994). Removing the BAK from IOP-lowering medi-
cations might reduce inﬂ  ammation and assist in reducing 
conjunctival vessel dilation; this hypothesis is supported 
by the lessened hyperemia observed in the study.
Overall, the incidence of patients discontinuing due to 
an adverse event related to travoprost BAK-free therapy was 
very low. Conjunctival hyperemia was the most commonly 
cited patient complaint (6%), as well as the most common 
adverse event leading to discontinuation (3%). However, 
this must be mentioned in the context that 4% of patients 
were diagnosed with conjunctival hyperemia at the baseline 
visit.
Visual acuity was also slightly improved after 3 
months of travoprost BAK-free therapy. The change was 
small and may have been by chance. However, if corneal 
tear film stability is improved by removal of the BAK, 
as indicated by Manni et al (2005), visual acuity may 
have improved as a result of changing to a BAK-free 
preparation.
This study suggests that patients previously treated 
with BAK-preserved prostaglandin analog therapy and 
subsequently changed to travoprost BAK-free had, on 
average, similar to slightly better IOP control while 
experiencing reduced anterior segment symptoms and 
lessened hyperemia.
The study did not evaluate differences in efﬁ  cacy and 
safety between BAK-free travoprost and other prostaglandin 
therapy in a parallel, randomized, masked fashion. The 
change in therapeutic regimen may have fostered the expecta-
tion in some patients of a superior therapy, possibly resulting 
in more favorable subjective outcomes than may have been 
observed in a randomized, double-masked study. More 
research is needed in an adequately controlled prospective 
trial to conﬁ  rm the ﬁ  ndings noted in this study. In addition, 
this study was not designed to address the long-term clinical 
outcomes of travoprost BAK-free therapy. Further research 
with prostaglandin analogs will clarify the best therapeutic 
approach with this class of medicine for patients with 
glaucoma or ocular hypertension.
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